U.S. Markets closed

Sanofi Eczema Drug Dupixent's sBLA Gets Priority Review

Zacks Equity Research
Sanofi (SNY) and partner Regeneron announce priority review to label expansion application of Dupixent seeking approval in adolescent patients with moderate-to-severe atopic dermatitis.

Sanofi SNY and partner Regeneron Pharmaceuticals REGN announced that the FDA has granted a priority review to its atopic dermatitis drug Dupixent’s (dupilumab) supplemental Biologics License Application (sBLA). The sBLA is seeking label expansion of the drug to include adolescent patients who are 12 years to 17 years of age with moderate-to-severe atopic dermatitis (eczema) and whose disease could not be adequately controlled with topical medications or for whom topical treatment was medically inadvisable. A decision from the FDA on approval of the sBLA is expected by Mar 11, 2019.

The sBLA was based on positive data from a phase III study, which evaluated Dupixent monotherapy. Data showed that signs and symptoms of atopic dermatitis and certain quality of life measures in adolescent patients treated with the drug were significantly improved.

We remind investors that the drug is already approved in the United States and Europe for treating adult patients in similar indication.

Please note that the priority review designation from the FDA is generally granted to drugs with potential to provide significant improvements in the safety and effectiveness of the treatment plus prevention or diagnosis of a serious disease.

Dupixent has shown strong growth so far this year. An expanded patient population will certainly boost the prospects of the drug further. Moreover, the company and partner Regeneron are also working to expand Dupixent’s label in other indications. In October, the FDA approved a label expansion of the drug as an add-on maintenance treatment in adults and adolescents (12 years of age or older) with moderate-to-severe asthma.

However, we note that several other pharma companies are also developing their candidates/drugs for the treatment of atopic dermatitis including Pfizer’s PFE JAK1 inhibitor (PF-04965842), Lilly’s LLY Olumiant and AbbVie’s upadacitinib.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
Sanofi (SNY) : Free Stock Analysis Report
Pfizer Inc. (PFE) : Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research